PDCD1 and non-small cell lung carcinoma: Nevertheless, the magnitude of OS benefits favoured the anti-PD-1/PD-L1 group most in patients with SCLC, revealing that the combination of anti-PD-1/PD-L1 and anti-CTLA-4 treatment has better therapeutic effects in patients with NSCLC.